Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
in vivo
Biotech
Novartis taps Vyriad’s viral vectors for in vivo T cell editing
For each program advanced by the Big Pharma, Vyriad will receive an upfront payment, milestone payments and royalties.
Darren Incorvaia
Nov 20, 2024 12:00pm
PharmaLegacy snaps up preclinical CRO
Sep 16, 2024 3:50pm
Sanofi, Scribe seal new in vivo collab worth more than $1.2B
Jul 17, 2023 11:30am
George Church-founded biotech tacks on $40M series A
Jul 14, 2022 8:00am
Novartis pays $75M to form sickle cell in vivo gene editing pact
Jun 22, 2022 3:40am
Moderna, Excision each enter HIV battle with mRNA, CRISPR tech
Jan 27, 2022 11:02am
